Are you ready for what's coming?
The Rise of Decentralized Science: Unlocking a New $ONC Era for Oncology Research 🔬
Read the new blog post and let's get ready! Link:
https://t.co/8Q7LJw4VvN
We are inviting researchers and experts to contribute under the Types and Causes of #Cancer session at the #Cancerconference from May 04-05, 2026, Kuala Lumpur, Malaysia
More info at https://t.co/f1mFXw3qCd
Let's connect with global studies!
#cancercauses#oncology#cancercare
📢Have you registered for the upcoming Exact Sciences webinar?
▶️Join Dr. Stephen Noga from Exact Sciences for a webinar on September 9th at 8pm ET / 5pm PT to learn about molecular residual disease (MRD) testing and the new OncodetectTM test for patients with colorectal cancer. Attend the webinar to learn:
➡️ The biology and technology supporting MRD testing
➡️ An overview of the Oncodetect MRD test
➡️ Analytical and clinical validation of the test
➡️ The prognostic value of MRD testing in CRC
📍 This webinar will be moderated by CGA-IGC member, Jessica Long.
⏩ Register here today👉 https://t.co/UNNv8vk7lm
#HereditaryGICancer
@GIOncologist@oncologynet@oncology
When my mother was first diagnosed with cancer, I was very young. I still remember the moment when the doctor said, “Let’s see how much time we have left.” Those words shook me, though I didn’t fully understand the depth of it then. But as I looked at my brother and sister, I realized one thing: as the elder daughter, I had to be strong for them, hide my pain, and take responsibility.
What I didn’t know back then was that cancer would not end with one treatment. It kept returning, testing every member of my family—especially me. I learned to carry my pain quietly, while showing strength on the outside.
Today, when I hear the word “cancer,” it no longer weakens me—it gives me strength. It reminds me of my purpose: to serve society, to stand with others in their fight. With a proud and grateful heart, I can say that I have provided free diet plans to 5,035 cancer patients. Through my knowledge and education, I’ve supported them not only with nutrition but also with moral strength—because I see each of them as part of my own family.
I truly believe this is a blessing—for me, for my mother, and for everyone I serve. Thank you, God, for shaping me into the person I am today, and for giving me the opportunity to help every cancer patient who crosses my path. I am proud, and I am deeply grateful.
#cancer @theNCI@StopCancerDoc@oncologynet@CR_UK #cancerawarness
This is where new science meets new tech:
📊 Blockchain for secure health records
🤖 AI for pattern recognition in recovery
🌐 DeSci collaboration for breakthroughs
Together, they form the foundation of modern healing.
#AIHealth#HealingRevolution
🎙️ New Immunobuddies Episode!
EP153: Subcutaneous Immunotherapy – Future Potential
What could the future of cancer treatment look like? 💉✨
Jo Parkes & Dr Vasiliki Michalarea return to explore how subcutaneous (SC) immunotherapy might transform care delivery, reduce hospital visits, and improve patient access – but what will it take to scale?
🔍 Clinical insight
🏥 System-level impact
👩⚕️ Patient-centred benefits
🎧 Listen now: https://t.co/jHNcwO2aEN
@AOlssonBrown@RickyFrazer1@BOPACommittee @UKAOSociety @IOClinicalNet@myESMO@oncologynet@io_hub@ImmunooncologyW@radchat@OncEd@OncologyNT@VCCLibrary@VelindreCS
#Immunobuddies #Immunotherapy #Oncology #Subcutaneous #CancerResearch #IO #Podcast #OncoPharma #MedicalInnovation #SubcutaneousImmunotherapy #OncologyPodcast #IOdelivery #PharmacyInnovation #CancerCare #InnovationInHealth
🏳️🌈#LGBTQ+ patients navigate #cancer care through a maze of discrimination, provider bias, and systemic barriers that delay life-saving diagnoses. When healthcare becomes truly inclusive, survival rates soar. Every patient deserves dignity in their darkest hour.
#cancerequality
🎧 NEW EPISODE OUT NOW!
Is Subcutaneous Immunotherapy a Game-Changer or Just Hype? 💉🤔
Join @RickyFrazer1 & @AOlssonBrown as they unpack the science, promise & pitfalls of Subcutaneous Immunotherapy with special guests Jo Parkes & Dr Vasiliki Michalarea.
We’re diving into:
✅ The role of Subcutaneous Immunotherapy in cancer
✅ Real-world logistics & patient selection
✅ Innovations redefining injectable immune treatments
✅ Is it the future—or just a fad?
Don’t miss this bold conversation on Episode 151 of The @immunobuddies ! 🧬✨
🎙️ Listen now: https://t.co/kv6YGAV1FN
#Immunobuddies #Subcutaneous #Immunotherapy #Oncology #CancerCare #MedTwitter #ImmunoOncology #Podcast @UKONSmember@BOPACommittee @UKAOSociety @IOClinicalNet@myESMO@oncologynet@io_hub@ImmunooncologyW@radchat@OncEd
TSX Top Gainers & Losers: Today's Market Highlights
📈 Top 7 Gainers:
1. $G +25.56% (+$0.34) at $1.67
2. $IMP +12.59% (+$0.35) at $3.13
3. $LAC +8.67% (+$0.34) at $4.26
4. $ONC +7.19% (+$0.11) at $1.64
5. $RVX +6.67% (+$0.01) at $0.08
6. $GLXY +6.11% (+$1.75) at $30.40
7. $FOOD +5.88% (+$0.01) at $0.18
📉 Top 7 Losers:
1. $KRN -10.71% (-$0.02) at $0.13
2. $EXRO -8.33% (-$0.01) at $0.06
3. $SVM -7.75% (-$0.54) at $6.43
4. $SFD -7.04% (-$0.05) at $0.66
5. $BCHT -6.90% (-$0.06) at $0.81
6. $CJR.B -5.00% (-$0.01) at $0.10
7. $FT -5.00% (-$0.01) at $0.10
➡️ Find out which broker is best to trade these stocks: https://t.co/kQgXePApZY
🔔 Baker Bros. Q1 ‘25* Holdings Released... 🐳
» Holdings: 89
» Holdings in Top 20: 91.02%
» Qtr over Qtr Change**: -3.47% ⬇️
🚀 Top Holdings:
$ONC
$INCY
$ACAD
$MDGL
$SMMT
$INSM
$RYTM
$RVMD
$KYMR
$ALKS
$EWTX
$REPL
$INSM
$IMVT
$BCYC
$IMCR
$KNSA
$ABCL
$RARE
$DNLI
*Holdings as of 3/31/25 in SEC form 13F
**Change in value of public company shares held
See image for more details! 📸👇
"#CancerVaccines and the future of immunotherapy" super review at @TheLancet is a great article (just had a chance to read it).
As its pay-per-view article I'm not allowed to make it public.
I will point out key lessons learned for everyone interested in the subject:
🫵More effective cancer vaccines are being developed through having a deeper understanding of crucial cellular factors in #tumor #immunology;
🫵#CancerVaccines generally aim to deliver #antigens to #dendritic #cells, which are the most potent activators of #antigen-specific #Tcells. Once the T cells are activated, they will expand, mobilise, and kill cancer cells systemically;
🫵Newer #vaccines are being designed to improve the expansion of #cancer-killing #Tcells and overcome the tumoural resistance mechanisms;
🫵#Cancer #Vaccines are an important modality in the #immunotherapy arsenal by enhancing the strength and breadth of anti-tumour T-cell responses, prolonging #remissions in the #adjuvant setting, and inducing systemic #regressions of #metastatic #solid #tumors and #hematological cancers;
🫵#CancerVaccines will undoubtedly become more effective in the coming decade as we further establish the biological understanding and technical capabilities for total programmable control of anti-tumor immune responses.
@TheLancet@TheLancetOncol@ASCO@JCOGO_ASCO@ASCOPost@myESMO@EuropeanCancer@AACR@ConquerCancerFd@SU2C@AmericanCancer@theNCI@CDC_Cancer@BidenCancer@CR_UK@jitcancer@sitcancer@US_FDA@FDAOncology@EMA_News@oncodaily@OncoAlert@biospace@FierceBiotech@FiercePharma@Labiotech_eu@MedscapeOnc@oncologynet@EUeic@EIF_EU@EIB@EU_EISMEA@ERC_Research@EITHealth@EITeu@VaccinesToday@gavi